Objectives
Previous studies have shown a familial component in rheumatoid arthritis (RA) and in some other rheumatic autoimmune diseases (RAIDs) but because of various study designs the risk estimates for familial risks differ extensively.
Methods
We collected data on patients diagnosed in Swedish hospitals with RA, ankylosing spondylitis (AS), polymyosistis/dermatomyosistis (PM/DM), Sjogren syndrome (SS), systemic lupus erythematosus (SLE) and systemic sclerosis (SyS, scleroderma) and calculated familial standardized incidence ratios (SIRs) for each of these (concordant) and between them (discordant).
Results
The combined number of RAID patients in the offspring population (for whom SIRs were calculated) was 71,544 and in the whole population the number was 152,714, accounting for 19.8% of all AIDs in Sweden. AS showed the highest concordant familial risk of 18.42, followed by SLE (14.04), SS (8.63), SyS (4.50), PM/DM (4.03) and RA (3.03). There were no sex difference in SIRs. Risks for AS and SLE were 80.28 and 19.53 for persons whose parents and siblings were affected. Discordant risks were far lower than concordant risks but they were significant for RA with all other 5 RAIDs, for SLE and SyS with 4 RAIDs, for AS and SS with 3 RAIDs and for PM/DM with 2 RAIDs, attesting to extensive polyautoimmunity between RAIDs.
Conclusions
The derived familial risks in this nation-wide family study on medically diagnosed RAID are compatible with emerging evidence on the polygenic background of these complex diseases. Novel genetic pathways offer new therapeutic targets that optimally alleviate disease onset in high-risk familial patients and others.